How and when to pace in vasovagal syncope

Journal of Cardiovascular Electrophysiology

Volumn 13, Issue 1 SUPPL., 2002, Pages

  Sutton, Richard ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Pacing; Vasovagal syncope

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUDROCORTISONE; MIDODRINE; PAROXETINE;

ADULT; ARTIFICIAL HEART PACEMAKER; CLINICAL TRIAL; CONFERENCE PAPER; DEVICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; HEART OUTPUT; HEART PACING; HEART RATE VARIABILITY; HUMAN; HYSTERESIS; PRIORITY JOURNAL; SINUS TACHYCARDIA; SYNCOPE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 0036152777     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2002.tb01947.x     Document Type: Conference Paper

References (32)

1. Syncope: Physiological considerations and an analysis of the clinical characteristics in 510 patients
2. The clinical spectrum of neurocardiogenic syncope
3. Vasovagal syncope and the carotid sinus mechanism: With comments on Gower's and Nothnagel's syndrome
4. Evaluation and outcome of emergency room patients with transient loss of consciousness
5. Clinical characteristics of patients with vasovagal reactions presenting as unexplained syncope
6. Syncope: History may be inaccurate in elderly people
7. Permanent pacing for cardio-inhibitory malignant vasovagal syndrome
8. Vasovagal syncope - Could it be malignant?
9. Head-up tilt: A useful test for investigating unexplained syncope
10. Value of head-up tilt testing potentiated with sublingual nitroglycerin to assess the origin of unexplained syncope
11. Tilt-table testing for assessing syncope. An American College of Cardiology expert consensus document
12. Proposed classification for vasovagal syncope
13. New classification of haemodynamics of vasovagal syncope: Beyond the VASIS classification. Analysis of the presyncopal phase of the tilt test with and without nitroglycerin challenge
14. Dual chamber pacing aborts vasovagal syncope induced by head-up 60 degree tilt
15. Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vasovagal) syncope
16. Components of clinical trials for vasovagal syncope
17. Age and gender differences in basal and isoprenaline protocols for head-up tilt table testing
18. Dual chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope: Pacemaker versus no therapy. A multicenter randomised study
19. Is there an effective pharmacological treatment in the prevention of vasovagal syncope?
20. Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: A prospective, double-blind, randomized and placebo-controlled study
21. Effect of etilefrene in preventing syncopal recurrence in patients with vasovagal syncope: A double blind, randomised, placebo-controlled trial
22. Randomised double blind placebo controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table results
23. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: A randomised double-blind, placebo-controlled study
24. Midodrine: A role in the management of neurocardiogenic syncope
25. Tilt training: A treatment for malignant and recurrent neurocardiogenic syncope
26. The North American Vasovagal Pacemaker Study (VPS). A randomised trial of permanent cardiac pacing for the prevention of vasovagal syncope
27. Recurrent symptoms after ventricular pacing in unexplained syncope
28. Comparison of single and dual chamber pacing techniques in prevention of upright tilt induced vasovagal syncope
29. First steps toward a pacing algorithm for vasovagal syncope
30. "Rate drop response" cardiac pacing for vasovagal syncope
31. Respiratory changes in vasovagal syncope